Back

Comparative safety and efficacy of combination lipid lowering therapy versus high-intensity statin in elderly patients with atherosclerotic cardiovascular disease

30 August 2025 (11:15 - 12:00)
Organised by: Logo
Congress Presentation Part of: Cardiovascular disease in older adults (1) Cardiovascular Disease in the Elderly ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Jung-Joon Cha

Korea University Anam Hospital, Seoul (Korea (Republic of))

7 More presentations in this session

Presentation thumbnail
Association of GlycA, a composite 1H-NMR marker of systemic inflammation, with LDL particle size, frailty and epigenetic age acceleration
Associate Professor E. Fung (Hong Kong, CN)
Abstract Slides Video
Presentation thumbnail
Clinical outcomes of drug-coated balloon vs. drug-eluting stent in octogenarians with coronary artery disease: a propensity score-matched study
Professor A. Her (Chuncheon, KR)
Abstract Slides Video
Presentation thumbnail
Baseline levels of amino acid metabolites are associated with clinical outcomes in older persons
Doctor C. Wang (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Diagnostic value of 24-hour holter monitoring in nonagenarians: a single-center cohort study
Doctor A. Fonseca Vazao (Leiria, PT)
Abstract Slides Video
Presentation thumbnail
Combined effect of frailty and sarcopenia on the risk of cardiovascular disease: a longitude analysis in middle-aged and older adults
Miss M. Liu (Beijing, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiovascular disease in older adults (1)

The Event

Event poster

ESC Congress 2025

30 August 2025 11:15 CET
You may be interested in
thumbnail
Congress Session
Refining efficacy and safety of lipid-lowering pharmacotherapy
thumbnail
Congress Presentation
Combination of moderate-intensity statins and ezetimibe versus high-intensity statins alone for primary prevention of cardiovascular events
thumbnail
Congress Session
Changing face of lipid-lowering therapy

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources